pp-102 Injection
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
Comments
Indication: Advanced or metastatic non-small cell lung cancer (NSCLC), primarily as part of combination immunotherapy regimens in patients with progressive disease.
Clinical stage: Phase 2 global clinical development
Modality: mRNA-based cancer immunotherapy (therapeutic vaccine)
Mechanism / Target: Encodes multiple tumor-associated antigens to stimulate antigen-specific T-cell responses against lung cancer cells.
Route / form: Intravenous administration (lipid nanoparticle–formulated mRNA vaccine)
Differentiation: Multi-antigen mRNA vaccine designed to induce broad anti-tumor immune responses and enhance checkpoint inhibitor efficacy in NSCLC.
Manufacturer #38937
Clinical-stage biotechnology company focused on mRNA therapeutics and immunotherapies, primarily in oncology and infectious diseases. Develops precision medicines designed to activate or direct immune responses against disease targets. Strategy emphasizes global clinical development and strategic partnerships.